The treatment of de novo acromegalic patients with octreotide-LAR: Efficacy, tolerability and cardiovascular effects

Pituitary

Volumn 6, Issue 1, 2003, Pages 11-18

  Gilbert, J ^a   Ketchen, M ^a   Kane, P ^a   Mason, T ^a   Baister, E ^a   Monaghan, M ^a   Barr, S ^a   Harris, Philip E ^a,b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Acromegaly; Cardiovascular; De novo treatment; GH; IGF I; Octreotide LAR

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR FUNCTION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CONTROL; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; FATIGUE; FEMALE; GROWTH INHIBITION; HEALTH STATUS; HEART EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HUMAN; M MODE ECHOCARDIOGRAPHY; MALE; MEDICAL ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY OF LIFE; SWEATING; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ACROMEGALY; ADENOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PITUITARY NEOPLASMS; PROSPECTIVE STUDIES; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 0344825807     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026273509058     Document Type: Article

References (43)

1. Wright AD, Hill DM, Lowy C, Russell-Fraser T. Mortality in acromegaly. Quarterly Journal of Medicine 1970;153:1-16.
2. Bengtsson B, Eden S, Ernest I, Oden A, Sjogren B. Epidemiology and longterm survival in acromegaly. Acta Medicus Scandinavia 1988;233:327-335.
3. Colao, A, Cuocolo A, Marzullo P. Impact of patient's age and disease duration on cardiac performance in acromegaly: A radionuclide angiography study. J Clin Endocrinol Metab 1999;184:1518-1526.
4. Minniti G, Jaffrain-Rea ML, Moroni C, Baldelli R, Terretti E, Cassone Retal. Echocardiographic evidence for a direct effect of GH/IGF 1 hypersecretion on cardiac mass and function in young acromegalics. Clin Endocrinol 1998;49:101-106.
5. Bates AS, Vant, Hoff W, Jones JM, Clayton RN. Audit of outcome of treatment in acromegaly. Quarterly Journal of Medicine 1993;86:293-299.
6. Swearingen B, Barker FC, Laurence K, Beverly M, Biller K, Grinspoon S et al. Long term mortality after Trans-sphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419-3426.
7. Sheppard MC. Aims of treatment and definition of cure in treating acromegaly; 100 years on. In: Wass J, ed. Society for Endocrinology Bristol, 1994:17-23.
8. Wass JAH. Acromegaly treatment after 100 years. British Medical Journal 1993;307:1505-1506.
9. Osman IS, James RA, Chatterjee S, Mathias D, Kendall-Taylor P. Factors determining the long-term outcome of surgery in acromegaly. Quarterly Journal of Medicine 1994;87:617-623.
10. Ahmed A, Elsheikh M, Page RC, Adams CBT, Wass JAH. Outcome of trans-sphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol 1999;50:561-567.
11. Wass JA. Evidence for the effectiveness of radiotherapy in the treatment of acromegaly. J Endocrinol 1997;155(Suppl):S57-58.
12. Vance ML, Harris AG. Long term treatment of 189 acromegalic patients with the somatostatin analogue octreotide. Archives of Internal Medicine 1991;151:1573-1578.
13. Newman CB, Melmed S, Snyder PJ, Young WF et al. Safety and efficacy of long-term octreotide therapy of acromegaly: Results of a multicentre trial in 103 patients. J Clin Endocrinol Metab 1995;80:2768-2775.
14. Caron PH, Beckers A, Cullen DR, Goth MI, Gutt B et al. Efficacy of the New Long-Acting Formulation of Lanreotide (Lanreotide Autogel) in the Management of Acromegaly. J Clin Endocrinol Metab 2002;87:99-104.
15. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC. Depot long-acting somatostain analog (Sandostatin LAR) is an effective treatment for acromegaly. J Clin Endocrinal Metab 1995;80(11):3267-3272.
16. Newman CB, Melmed S, George A, Tonia D, Duhaney M, Snyder P et al. Octerotide as primary treatment for acromegaly. J Clin Endocrinol Metab 1998;83:3034-3040.
17. Davies PH, Stewart SE, Lancranjan I, Shepperd MC, Stewart PM. Longterm therapy with long acting octreotide (Sandostatin LAR for the management of acromegaly). Clin Endocrinol 1998;48:311-316.
18. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V et al. Long-term effects of depot long-acting somatostatin analogue octreotide on hormone levels and tumour mass in acromegaly. J Clin Endocrinol Metab 2001;86:2779-2785.
19. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F et al. Primary medical therapy for acromegaly: An open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002;87:4554-4563.
20. Szucs N, Meszaros J, Czirjak S, Mondok A, Varga I, Glaz E. Experience in treating acromegalic patients with long-acting octroetide. Orv Hetil 2002;12;143:1066-1070.
21. Merola B, Cittadini A, Colao A. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J Clin Endocrinol Metab 1993;177:790-793.
22. Tokgozoglu SL, Erbas T, Aytemir K. Effects of octreotide on left ventricular mass in acromegaly. American Journal of Cardiology 1994;74:1072-1074.
23. Baldelli R, Feretti E, Jaffrain-Rea ML. Cardiac effects of lanreotide, a slow release somatostatin analog in acromegalic patients. J Clin Endocrinol Metab 1999;184:527-532.
24. Hradec J, Kral J, Janota. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow release somatostatin analog). American Journal of Cardiology 1999;83:1506-1509.
25. Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab 2000;85:3132-3140.
26. Ware JE. SF36 Health Survey-Manual and Interpretation Guide. Boston: MA Health Assessment Laboratory, 1993.
27. Shan D, De Maria A, Kisslo J, Wegman A. The Committee on M-mode standardization of the American Society of Echocardiography, "Recommendations regarding quantification in M-mode echocardiography, results of a survey of echocardiographic measurements." Circulation 1978;58(6):1072-1083.
28. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L et al. CONSENSUS Guidelines for Acromegaly Management. J Clin Endocrinol Metab 2002;87:4054-4058.
29. Colao A, Ferone D, Cappabiana P, del Basso De Caro ML, Marzullo P et al. Octreotide as Primary Therapy for Acromegaly. J Clin Endocrinol Metab 1998;83:3034-3040.
30. Auk J, Stewart SE, Stewart PM, Sheppard MC. Long-Term Safety and Efficacy of Depot Long-Acting Somatostatin Analogs for the Treatment of Acromegaly. J Clin Endocrinol Metab 2002;87:4142-4146.
31. Lancranjan I, Atkinson AB, Sandostatin LAR Group. Results of a European multicentre study with sandostatin LAR in acromegalic patients. Pituitary 1999;1:105-114.
32. Lancranjan I, Bruns C, Grass P, Jaquet P, Jervell J, Kendall-Taylor P et al. Sandostatin LAR: A promising therapeutic tool in the management of acromegalic patients. Metabolism 1996;45:67-71.
33. Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drug 1997;153:681-699.
34. Plockinger U, Reichel M, Fett U, Saeger W, Quabbe HJ. Pre-operative octreotide treatment of growth hormone-secreting and clinically non functioning pituitary macroadenomas; effect on tumour volume and lack of correlation with immunohistochermistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 1994;79:1416-1423.
35. Colao, Ferone D, Lastoria S, Marzullo P, Cerbone G, Di-Sarno A et al. Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 1996;81:2356-2362.
36. Jenkins PJ, Akker S, Chew SL, Besser GM, Monson JP, Grossman A. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration Clinical Journal of Endocrinology (Oxf) 2000;53:719-724.
37. Flogstad AK, Halse J, Haldorsen T, Lancranjan I, Marbach P, Bruns C et al. Sandostatin LAR in acromegalic patients: A dose-range study. J Clin Endocrinol Metab 1995;80(12):3601-3607.
38. Flostad AK, Halse J, Bakke S, Lancranjan I, Marbich O, Bruns C et al. Sandostatin LAR in acromegalic patient; long term treatment. J Clin Endocrinol Metab 1997;82:23-28.
39. Sacca L, Ciittadini A, Fazio S. Growth hormone and the heart. Endocr Rev 1994;15:555-573.
40. Lombardi G, Colao A, Marzullo P, Ferone D, Longobardi S, Esposito V et al. Is growth hormone bad for your heart: Cardiovascular impact of GH deficiency and acromegaly. J Endocrinol 1997;(Suppl.1):S33-S37.
41. Kahaly G, Olshausen KV, Mohr-Kahaly S, Erbel R, Boor S, Beyer J et al. Arrhythmia profile in acromegaly. European Heart Journal 1992;13:51-56.
42. Demirats E, Sag C, Kursaklioglu H et al. Effects of octreotide in patients with hypertrophic obstructive cardiomyopathy. Japanese Heart Journal 1998;39:173-181.
43. Calao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte AM et al. Is the acromegalic cadiomyopathy reversible? Effect of 5 year normalisation of growth hormone and insulin-like growth factor I levels on cardiac performance. J Clin Endocrinol Metab 2001;86:1551-1557.